Hypofractionated radiotherapy can halve treatment time for poor performance status lung cancer patients

For patients with stage II and III non-small cell lung cancer unable to receive standard treatments of surgery or chemoradiation, hypofractionated radiotherapy results in similar overall survival and progression-free survival rates, limited severe side effects and shorter treatment times when compared to conventional radiotherapy, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).